Drug intelligence / Profile preview

BBRP11031

Development stage: Unknown
Lead developer: Benobio
Modality: Small Molecules
Administration: Unknown / Not Specified

Overview

BBRP11031 is an investigational antineoplastic drug developed by Benobio Co., Ltd. It is being developed primarily for the treatment of pancreatic cancer and possibly colon cancer. The drug's mechanism of action is currently undefined or unknown, but it involves epigenetic regulation technology. It is a novel molecular entity in preclinical and early clinical development stages, with the highest reported development phase being Phase 1 clinical trials as of 2025. The drug targets neoplasms and digestive system disorders among other metabolic diseases[1][2][3].

Other names: BBRP-11031BBRP11031BBRP 11031

Targets

BRD4 (Bromodomain-containing protein 4)

Beyond the preview

Go deeper on BBRP11031.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BBRP11031.

Explore the full profile